SAN

78.07

-1.3%↓

SRT3

208.8

-2.84%↓

ORNBV.FI

66.15

-0.82%↓

SAN

78.07

-1.3%↓

SRT3

208.8

-2.84%↓

ORNBV.FI

66.15

-0.82%↓

SAN

78.07

-1.3%↓

SRT3

208.8

-2.84%↓

ORNBV.FI

66.15

-0.82%↓

SAN

78.07

-1.3%↓

SRT3

208.8

-2.84%↓

ORNBV.FI

66.15

-0.82%↓

SAN

78.07

-1.3%↓

SRT3

208.8

-2.84%↓

ORNBV.FI

66.15

-0.82%↓

Search

Laboratorios Farmaceuticos Rovi SA

Ouvert

SecteurSoins de santé

79.3 0.44

Résumé

Variation du prix de l'action

24h

Actuel

Min

78.55

Max

79.75

Chiffres clés

By Trading Economics

Revenu

-33M

43M

Ventes

7.9M

218M

P/E

Moyenne du Secteur

33.602

60.328

BPA

0.834

Marge bénéficiaire

19.539

Employés

1,950

EBITDA

-21M

63M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+7.5% upside

Dividendes

By Dow Jones

Prochains Résultats

6 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

79M

4.1B

Ouverture précédente

78.86

Clôture précédente

79.3

Sentiment de l'Actualité

By Acuity

50%

50%

177 / 348 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

28 avr. 2026, 23:33 UTC

Actions en Tendance

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28 avr. 2026, 23:24 UTC

Résultats

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28 avr. 2026, 23:15 UTC

Principaux Événements d'Actualité

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28 avr. 2026, 22:46 UTC

Résultats

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28 avr. 2026, 22:37 UTC

Résultats

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28 avr. 2026, 22:15 UTC

Résultats
Principaux Événements d'Actualité

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28 avr. 2026, 23:33 UTC

Market Talk
Principaux Événements d'Actualité

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28 avr. 2026, 23:31 UTC

Résultats

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28 avr. 2026, 23:31 UTC

Résultats

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28 avr. 2026, 23:30 UTC

Résultats

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28 avr. 2026, 23:30 UTC

Résultats

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28 avr. 2026, 23:19 UTC

Market Talk
Résultats

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28 avr. 2026, 23:09 UTC

Résultats

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28 avr. 2026, 23:03 UTC

Market Talk

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28 avr. 2026, 23:01 UTC

Principaux Événements d'Actualité

NIESR Sees One Rate Rise to 4% in Benign Scenario

28 avr. 2026, 23:01 UTC

Principaux Événements d'Actualité

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28 avr. 2026, 23:01 UTC

Principaux Événements d'Actualité

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28 avr. 2026, 23:01 UTC

Principaux Événements d'Actualité

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28 avr. 2026, 23:01 UTC

Principaux Événements d'Actualité

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28 avr. 2026, 22:51 UTC

Résultats

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28 avr. 2026, 22:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 avr. 2026, 22:48 UTC

Market Talk

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28 avr. 2026, 22:40 UTC

Market Talk
Principaux Événements d'Actualité

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28 avr. 2026, 22:32 UTC

Résultats

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28 avr. 2026, 22:25 UTC

Acquisitions, Fusions, Rachats

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28 avr. 2026, 22:22 UTC

Résultats

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28 avr. 2026, 22:17 UTC

Market Talk

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28 avr. 2026, 22:14 UTC

Résultats

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28 avr. 2026, 22:14 UTC

Résultats

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28 avr. 2026, 22:07 UTC

Market Talk
Principaux Événements d'Actualité

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

7.5% hausse

Prévisions sur 12 Mois

Moyen 86.75 EUR  7.5%

Haut 90 EUR

Bas 83.5 EUR

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

1

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

177 / 348Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
help-icon Live chat